GlassScriptPhysician profile
Heidi Cannan
NPI 1598258121
$3,717.74
in general payments reported to CMS, 2019-2025
34 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $1,062 · 2023: $1,038 · 2024: $636 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $671.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.25 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $544.27 | 2022-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $254.88 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $195.88 | 2021-2025 | Airsupra, Farxiga |
| Mylan Specialty L.P. | $123.51 | 2021-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $112.22 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.76 | 2021-2025 | Lifevest |
| Grifols USA, LLC | $92.78 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $83.52 | 2022-2025 | Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $82.19 | 2022-2024 | Glassia |
| Sk Life Science, INC. | $70.54 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $60.36 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $49.68 | 2022-2024 | Watchman Flx |
| Verona Pharma, INC. | $47.13 | 2025 | Ohtuvayre |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $45.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.16 | 2021 | |
| Lundbeck LLC | $41.48 | 2023 | Vyepti |
| Genzyme Corporation | $41.31 | 2022-2024 | |
| Pfizer INC. | $40.52 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.19 | 2025 | |
| Esperion Therapeutics, INC. | $39.16 | 2022 | |
| Scpharmaceuticals INC. | $39.01 | 2023-2025 | |
| Baxter Healthcare | $35.53 | 2023 | Hillrom - Life 2000 Ventilation System |
| Kiniksa Pharmaceuticals, LTD. | $23.34 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $23.09 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $22.51 | 2024 | Arcalyst |
| Lilly USA, LLC | $21.66 | 2022 | |
| Abbott Laboratories | $21.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.75 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.30 | 2021 | |
| Neurocrine Biosciences, INC. | $15.39 | 2024 | Ingrezza |
| Paratek Pharmaceuticals, INC. | $12.05 | 2021 | |
| Mdd US Operations, LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Cannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.